# Article information:

The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma - PubMed  
<https://pubmed.ncbi.nlm.nih.gov/31044626/>

# Article summary:

1. The expression of ILT4 in mDCs subsets was analyzed in 121 patients with hepatocellular carcinoma (HCC) and 103 normal controls.

2. The percentage of CD1c+ subset was significantly decreased in the peripheral blood mononuclear cells (PBMCs) of HCC patients compared to normal controls, and also significantly decreased in tumor tissue compared to the tumor free liver tissues (TFL).

3. The increased ILT4+CD1c+ subset in tumor tissue might play an important role in immune suppression for patients with HCC.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article is generally reliable and trustworthy, as it provides a detailed analysis of the expression of ILT4 in mDCs subsets in patients with hepatocellular carcinoma (HCC). It presents evidence from both clinical studies and laboratory experiments, which supports its claims that the percentage of CD1c+ subset is significantly decreased in the peripheral blood mononuclear cells (PBMCs) of HCC patients compared to normal controls, and also significantly decreased in tumor tissue compared to the tumor free liver tissues (TFL). Furthermore, it suggests that the increased ILT4+CD1c+ subset in tumor tissue might play an important role in immune suppression for patients with HCC.

The article does not appear to have any major biases or one-sided reporting, as it presents both sides equally and does not make any unsupported claims. It also provides a comprehensive overview of relevant research on this topic, including references to other studies that support its findings. Additionally, it does not appear to be promotional content or partiality towards any particular viewpoint or opinion.

The only potential issue is that some possible risks associated with this research are not noted or discussed. For example, there could be potential risks associated with using PolyI:C stimulation on PBMCs from HCC patients, which should be taken into consideration when interpreting the results of this study.

# Topics for further research:

* Hepatocellular carcinoma immune suppression
* ILT4 expression in mDCs
* CD1c+ subset in PBMCs
* PolyI:C stimulation risks
* TFL in HCC patients
* Immune response in HCC

# Report location:

<https://www.fullpicture.app/item/d3042e8cba34f9279e1e66372ff9319d>